AmacaThera Forms Partnership with Global Pharmaceutical Company to Develop Long-Acting Biologic Using Hydrogel Platform
Wednesday, April 09, 2025
AmacaThera, a clinical-stage biotechnology company focused on drug delivery, has entered into a new collaboration with a leading global pharmaceutical firm. The partnership aims to develop a long-acting, single-injection biologic using AmacaThera’s proprietary hydrogel delivery platform, AmacaGel™, combined with the pharmaceutical partner’s therapeutic product.
The development programme will be jointly funded and will draw on the combined expertise and resources of both organisations to support the rapid advancement of the biologic. AmacaThera’s hydrogel platform has undergone extensive testing with various types of therapeutics, including small molecules, biologics, and stem cells, through internal studies and academic research conducted at the University of Toronto.
This collaboration follows the successful completion of AmacaThera’s first-in-human Phase 1 trial, which tested AmacaGel™ with an anaesthetic. The study provided important human data on the performance of the hydrogel system and its integration with a therapeutic compound.
The agreement builds on AmacaThera’s existing manufacturing capabilities and the clinical data already gathered from its hydrogel platform. AmacaGel™ is noted for its compatibility with a wide range of drug types, its straightforward and scalable production process, and its cost-efficiency, all supported by real-world human data.
The partnership was made possible through CQDM’s Connect-Pharma initiative, which links Canadian companies and researchers with global pharmaceutical industry partners. CQDM is an organisation that supports collaboration and innovation in the biopharmaceutical sector. This new development highlights growing industry confidence in AmacaThera’s drug delivery technology.
Source: prnewswire.com
